Investor Presentaiton
HER3-DXd
Breast cancer Ph1/2 study data
Daiichi-Sankyo
ASCO 2022 Highlights
Clinically meaningful and durable responses were observed across breast cancer
subtypes, responses were seen across a broad range of HER3 expression
Anti-tumor activities (HR+/HER2-, TNBC, HER2+ cohorts)
■ HR+/HER2- (ORR 30%, mDOR 7.2m), TNBC (ORR 23%, mDOR 5.9m), HER2+ (ORR 43%, mDOR 8.3m)
60
40
20
0
-20
-40
-60
-80
-100
60
40
20
0
-20
-40
-60
-80
-100
a Patients with TNBC and HER2+ were all HER3-high.
TNBCa
Patients (n=51)
HR+/HER2-
HER3 Expression
High
Low
60
HER2+a
40
20
0
-20
-40
-60
-80
-100
Patients (n=13)
b Best percentage change from baseline in sum of diameters based on BICR for all target lesions identified is represented by patient. If any lesion measurement is missing at a post-baseline tumor assessment visit, that visit is not taken into consideration for best percent
change from baseline in sum of diameters.
DOR: duration of response, HR: hormone receptor, ORR: objective response rate, TNBC: triple negative breast cancer
26View entire presentation